Aileron Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 15.73 million compared to USD 27.33 million a year ago. Basic loss per share from continuing operations was USD 3.42 compared to USD 6.02 a year ago.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4.925 USD | -1.50% | +3.68% | +61.55% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+61.55% | 84.86M | |
-2.88% | 103B | |
+1.56% | 95.28B | |
+1.46% | 22.15B | |
-16.37% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.05% | 16.05B | |
+5.56% | 13.68B | |
+33.38% | 12.17B |
- Stock Market
- Equities
- ALRN Stock
- News Aileron Therapeutics, Inc.
- Aileron Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023